{"id":"NCT01265394","sponsor":"GE Healthcare","briefTitle":"Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects","officialTitle":"A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2011-03","completion":"2011-04","firstPosted":"2010-12-23","resultsPosted":"2013-06-21","lastUpdate":"2013-07-02"},"enrollment":218,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Healthy"],"interventions":[{"type":"DRUG","name":"[18F] Flutemetamol","otherNames":["AH110690"]}],"arms":[{"label":"(18F) Flutemetamol","type":"EXPERIMENTAL"}],"summary":"Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.","primaryOutcome":{"measure":"Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid","timeFrame":"PET scans performed on patients 90 minutes post Flutemetmol Administration","effectByArm":[{"arm":"Normal and Abnormal Reads With or Without Amyloid","deltaMin":181,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":181},"commonTop":["General Disorders and Administration Site Conditions","Vascular System Disorders","Vascular System Disorders-Flushing","Gastrointestinal disorders"]}}